BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1395 related articles for article (PubMed ID: 28468951)

  • 1. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.
    Dongiovanni P; Meroni M; Baselli GA; Bassani GA; Rametta R; Pietrelli A; Maggioni M; Facciotti F; Trunzo V; Badiali S; Fargion S; Gatti S; Valenti L
    Clin Sci (Lond); 2017 Jun; 131(12):1301-1315. PubMed ID: 28468951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance.
    Meroni M; Longo M; Erconi V; Valenti L; Gatti S; Fracanzani AL; Dongiovanni P
    Nutrients; 2019 Oct; 11(11):. PubMed ID: 31671785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice.
    Motiño O; Agra N; Brea Contreras R; Domínguez-Moreno M; García-Monzón C; Vargas-Castrillón J; Carnovale CE; Boscá L; Casado M; Mayoral R; Valdecantos MP; Valverde ÁM; Francés DE; Martín-Sanz P
    Biochim Biophys Acta; 2016 Sep; 1862(9):1710-23. PubMed ID: 27321932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice.
    Yang A; Yan X; Fan X; Shi Y; Huang T; Li W; Chen W; Jia J; You H
    Hepatol Int; 2021 Oct; 15(5):1122-1135. PubMed ID: 34014450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary glycotoxins exacerbate progression of experimental fatty liver disease.
    Leung C; Herath CB; Jia Z; Goodwin M; Mak KY; Watt MJ; Forbes JM; Angus PW
    J Hepatol; 2014 Apr; 60(4):832-8. PubMed ID: 24316518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
    Wei G; An P; Vaid KA; Nasser I; Huang P; Tan L; Zhao S; Schuppan D; Popov YV
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G174-G188. PubMed ID: 31630534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.
    Kim KH; Kim SH; Han DH; Jo YS; Lee YH; Lee MS
    Sci Rep; 2018 May; 8(1):6789. PubMed ID: 29717162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet.
    Ding Y; Sun X; Chen Y; Deng Y; Qian K
    Eur J Pharmacol; 2015 Aug; 761():405-12. PubMed ID: 25967348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocyte-specific deletion of Brg1 alleviates methionine-and-choline-deficient diet (MCD) induced non-alcoholic steatohepatitis in mice.
    Kong M; Chen X; Xu H; Wenping ; Fang M; Xu Y
    Biochem Biophys Res Commun; 2018 Sep; 503(1):344-351. PubMed ID: 29890136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
    Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
    Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans.
    Cruces-Sande M; Vila-Bedmar R; Arcones AC; González-Rodríguez Á; Rada P; Gutiérrez-de-Juan V; Vargas-Castrillón J; Iruzubieta P; Sánchez-González C; Formentini L; Crespo J; García-Monzón C; Martínez-Chantar ML; Valverde ÁM; Mayor F; Murga C
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3655-3667. PubMed ID: 30261289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Vsig4 attenuates macrophage-mediated hepatic inflammation and fibrosis in high fat diet (HFD)-induced mice.
    Li Y; Sun JP; Wang J; Lu WH; Xie LY; Lv J; Li HX; Yang SF
    Biochem Biophys Res Commun; 2019 Aug; 516(3):858-865. PubMed ID: 31266632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotinic alpha-7 acetylcholine receptor deficiency exacerbates hepatic inflammation and fibrosis in a mouse model of non-alcoholic steatohepatitis.
    Kimura K; Inaba Y; Watanabe H; Matsukawa T; Matsumoto M; Inoue H
    J Diabetes Investig; 2019 May; 10(3):659-666. PubMed ID: 30369082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
    Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
    Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis.
    Afonso MB; Rodrigues PM; Carvalho T; Caridade M; Borralho P; Cortez-Pinto H; Castro RE; Rodrigues CM
    Clin Sci (Lond); 2015 Oct; 129(8):721-39. PubMed ID: 26201023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geranylgeranyl diphosphate synthase (GGPPS) regulates non-alcoholic fatty liver disease (NAFLD)-fibrosis progression by determining hepatic glucose/fatty acid preference under high-fat diet conditions.
    Liu J; Jiang S; Zhao Y; Sun Q; Zhang J; Shen D; Wu J; Shen N; Fu X; Sun X; Yu D; Chen J; He J; Shi T; Ding Y; Fang L; Xue B; Li C
    J Pathol; 2018 Nov; 246(3):277-288. PubMed ID: 29971772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
    Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
    Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p16 deficiency promotes nonalcoholic steatohepatitis via regulation of hepatic oxidative stress.
    Lv F; Wu J; Miao D; An W; Wang Y
    Biochem Biophys Res Commun; 2017 Apr; 486(2):264-269. PubMed ID: 28286271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver-specific loss of Perilipin 2 alleviates diet-induced hepatic steatosis, inflammation, and fibrosis.
    Najt CP; Senthivinayagam S; Aljazi MB; Fader KA; Olenic SD; Brock JR; Lydic TA; Jones AD; Atshaves BP
    Am J Physiol Gastrointest Liver Physiol; 2016 May; 310(9):G726-38. PubMed ID: 26968211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.